AAREY DRUGS & PHARMACEUTICALS LTD.

Aarey Drugs & Pharmaceuticals Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from July 1, 2026, and will continue until 48 hours after the declaration of the Unaudited Financial Results for the quarter ended June 30, 2026. The move is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. Designated persons and their immediate relatives are prohibited from trading in the company's shares during this period to prevent insider trading.

Aarey Drugs & Pharmaceuticals Ltd's board approved the audited standalone financial results for the fourth quarter and year ended March 31, 2026. The company reported revenue from operations of ₹473.94 million and a profit of ₹3.96 million for the year ended March 31, 2026. The board meeting, which commenced at 5:00 P.M. and concluded at 7:20 P.M., also approved a statement of deviation or variation in utilization of funds raised through convertible warrants.

Aarey Drugs & Pharmaceuticals Ltd's board approved the audited standalone financial results for the fourth quarter and year ended March 31, 2026. The company's Revenue from Operations stood at ₹47,394.33 Lakhs for the year ended March 31, 2026. The board meeting, which commenced at 5:00 P.M. and concluded at 7:20 P.M., also approved a statement of deviation or variation in utilization of funds raised through convertible warrants.

Aarey Drugs & Pharmaceuticals Ltd's board approved the audited standalone financial results for the fourth quarter and year ended March 31, 2026. The company reported revenue from operations of ₹473.94 million and a profit after tax of ₹39.67 million for the year ended March 31, 2026. The board meeting, held on May 30, 2026, also took on record the statement of deviation or variation in utilization of funds raised through convertible warrants.

Aarey Drugs & Pharmaceuticals Ltd has rescheduled its Board of Directors meeting from May 29, 2026, to May 30, 2026, due to unavoidable circumstances. The board will consider and approve the audited financial results for the quarter and financial year ended March 31, 2026. The trading window remains closed and will open 48 hours after the financial results are announced.

Aarey Drugs & Pharmaceuticals Ltd has scheduled a Board of Directors meeting on May 29, 2026, to consider and approve the audited financial results for the quarter and financial year ended March 31, 2026. The trading window for dealing with the company's shares is currently closed and will reopen 48 hours after the announcement of the financial results.

Aarey Drugs & Pharmaceuticals Ltd has announced the closure of its trading window for insiders, designated persons, and their immediate relatives. The closure will take effect from Wednesday, April 01, 2026, until 48 hours after the declaration of the audited financial results for the fourth quarter and financial year ending March 31, 2026. The decision is in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the BSE and NSE circulars. Insiders are advised not to trade in the company's securities during this period. The board meeting date for the approval of the audited financial results will be announced in due course.

Aarey Drugs & Pharmaceuticals Ltd. has been fined ₹ 5,900 by the Bombay Stock Exchange (BSE) and National Stock Exchange of India Limited (NSE) for non-compliance with Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company failed to submit related party transactions in the specified format and within the prescribed timeline for the half year ended September 30, 2025. The fine is ₹ 5,000 plus GST (18%). The board has assured that necessary steps have been taken to strengthen internal compliance monitoring mechanisms to prevent recurrence of such instances.

Aarey Drugs & Pharmaceuticals Ltd has approved the unaudited financial results for the quarter ended 31st December, 2025. The company's revenue from operations stands at Rs. 9,642.63 Lakhs, with a profit before tax of Rs. 28,518.91 Lakhs. The company operates in the manufacturing and trading of drugs & pharmaceuticals and allied activities. The financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors.

Aarey Drugs & Pharmaceuticals Ltd. has announced its unaudited financial results for the quarter ended 31st December, 2025. The company's revenue from operations stands at Rs. 9,642.63 Lakhs, with a total income of Rs. 13,306.86 Lakhs. The total expenses for the quarter are Rs. 12,376.17 Lakhs, resulting in a profit before exceptional items and tax of Rs. 960.69 Lakhs. The company has purchased new fixed assets during the reporting period, but they are not yet ready for use, hence no depreciation has been charged. The company operates in one segment, manufacturing and trading of drugs & pharmaceuticals and allied activities. The figures of the previous year have been regrouped wherever necessary.